Global Alzheimer's Disease Diagnostic Market Professional Survey Report 2019

2 Global Alzheimer's Disease Diagnostic Quarterly Market Size Analysis

• 2.1 Alzheimer's Disease Diagnostic Business Impact Assessment - COVID-19
  • 2.1.1 Global Alzheimer's Disease Diagnostic Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Alzheimer's Disease Diagnostic Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Alzheimer's Disease Diagnostic Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Alzheimer's Disease Diagnostic Headquarters and Area Served
• 3.3 Date of Key Players Enter into Alzheimer's Disease Diagnostic Market
• 3.4 Key Players Alzheimer's Disease Diagnostic Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Alzheimer's Disease Diagnostic Segments, By Type

• 4.1 Introduction
  • 1.4.1 Genetic testing
  • 1.4.2 Neurological exam
  • 1.4.3 Mini-mental state exam (MMSE)
  • 1.4.4 Brain imaging
  • 1.4.5 Other
• 4.2 By Type, Global Alzheimer's Disease Diagnostic Market Size, 2019-2021

5 Impact of Covid-19 on Alzheimer's Disease Diagnostic Segments, By Application

• 5.1 Overview
  • 5.5.1 Clinics
  • 5.5.2 Hospitals
  • 5.5.3 Diagnostic Centers
  • 5.5.4 Other
• 5.2 By Application, Global Alzheimer's Disease Diagnostic Market Size, 2019-2021
  • 5.2.1 By Application, Global Alzheimer's Disease Diagnostic Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Eli Lilly
  • 7.1.1 Eli Lilly Business Overview
  • 7.1.2 Eli Lilly Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
  • 7.1.3 Eli Lilly Alzheimer's Disease Diagnostic Product Introduction
  • 7.1.4 Eli Lilly Response to COVID-19 and Related Developments
• 7.2 TauRx
  • 7.2.1 TauRx Business Overview
  • 7.2.2 TauRx Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
  • 7.2.3 TauRx Alzheimer's Disease Diagnostic Product Introduction
  • 7.2.4 TauRx Response to COVID-19 and Related Developments
• 7.3 Alector
  • 7.3.1 Alector Business Overview
  • 7.3.2 Alector Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
  • 7.3.3 Alector Alzheimer's Disease Diagnostic Product Introduction
  • 7.3.4 Alector Response to COVID-19 and Related Developments
• 7.4 Accera
  • 7.4.1 Accera Business Overview
  • 7.4.2 Accera Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
  • 7.4.3 Accera Alzheimer's Disease Diagnostic Product Introduction
  • 7.4.4 Accera Response to COVID-19 and Related Developments
• 7.5 Treventis
  • 7.5.1 Treventis Business Overview
  • 7.5.2 Treventis Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
  • 7.5.3 Treventis Alzheimer's Disease Diagnostic Product Introduction
  • 7.5.4 Treventis Response to COVID-19 and Related Developments
• 7.6 Neuro-Bio
  • 7.6.1 Neuro-Bio Business Overview
  • 7.6.2 Neuro-Bio Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
  • 7.6.3 Neuro-Bio Alzheimer's Disease Diagnostic Product Introduction
  • 7.6.4 Neuro-Bio Response to COVID-19 and Related Developments
• 7.7 Cognition Therapeutics
  • 7.7.1 Cognition Therapeutics Business Overview
  • 7.7.2 Cognition Therapeutics Alzheimer's Disease Diagnostic Quarterly Revenue, 2020
  • 7.7.3 Cognition Therapeutics Alzheimer's Disease Diagnostic Product Introduction
  • 7.7.4 Cognition Therapeutics Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US